Beam Therapeutics Inc. - Common Stock (BEAM) — AI analysis & news
Beam Therapeutics Inc. - Common Stock (BEAM) stock: 12 recent news items, slightly positive aggregate sentiment, AI analysis and market context on BestAIBroker.
Current sentiment read
Across the last 12 indexed BEAM stories, aggregate finance-aware sentiment is slightly positive (+0.15 on a -1 to +1 scale).
Latest BEAM news
- Roth/MKM initiates Atrium Therapeutics stock with buy rating By Investing.com - Investing.com UK · Investing.com UK
- Form 144 BEAM THERAPEUTICS INC. For: 17 October By Investing.com - Investing.com Nigeria · Investing.com Nigeria
- Nvidia-Backed AI Biotech Iambic Up 16% After $150 Million IPO · Bloomberg
- Bambusa Therapeutics Files for IPO to Fund Eczema Drug Trials · Bloomberg
- Why is Definium Therapeutics stock gaining today? - Investing.com · Investing.com
- Why is Atrium Therapeutics stock surging today? - Investing.com · Investing.com
- Why is Atrium Therapeutics stock surging today? By Investing.com - Investing.com India · Investing.com India
- Atrium Therapeutics raises $50 million in private placement By Investing.com - Investing.com UK · Investing.com UK
- Nektar Therapeutics stock analysis: oversold technicals meet binary clinical risk - Investing.com · Investing.com
- Nektar Therapeutics stock analysis: oversold technicals meet binary clinical risk - Investing.com India · Investing.com India
- Beam Therapeutics sues base editing rival, claims former scientist stole secrets - Fierce Biotech · Fierce Biotech
- Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property - STAT · STAT
FAQ
What is the current sentiment for BEAM stock?
Aggregate finance-aware sentiment across the last 12 indexed BEAM news stories is slightly positive (+0.15 on a -1 to +1 scale).